VolitionRx Limited Welcomes New Distribution Partnership
VolitionRx Limited (NYSE AMERICAN: VNRX), a pioneering company in the field of epigenetics, has announced an exciting new partnership with Medical & Biological Laboratories Co. Ltd (MBL). This collaboration marks MBL as a non-exclusive distributor for Volition's innovative Nu.Q® Discover assays in Japan.
Impact of the Partnership on Disease Research
Dr. Jasmine Kway, the Chief Executive Officer of Volition in Singapore, expressed her enthusiasm about the partnership, highlighting MBL's significant contributions to clinical research in Japan, especially in the area of autoimmune diseases. This partnership is expected to not only expand Volition's reach within the Japanese market but also positively impact drug development and disease research.
Navigating the Nu.Q® Discover Platform
The Nu.Q® Discover pillar of Volition serves nearly 100 clients globally, including several top pharmaceutical and diagnostic enterprises. These companies are utilizing the assays to accelerate their research and development processes, particularly in late-stage clinical trials where the assays act as pharmacodynamic biomarkers.
Growth Trends and Market Potential
Volition has calculated the Total Accessible Market for companion diagnostics to be just below $1 billion. In recent years, particularly through 2025, the company experienced significant revenue growth attributed to Nu.Q® Discover, with expectations for similar growth in subsequent years. This promising trajectory highlights the increasing relevance of their products in the diagnostics market.
Innovations within Nu.Q® Discover
The Nu.Q® Discover initiative is designed to provide researchers and pharmaceutical developers with access to sophisticated assays for faster epigenetic profiling, essential for the development of new drugs and therapies. These assays utilize proprietary nucleosome quantification technology, making them a vital resource for professionals in pharmacogenomics.
Key Milestones Achieved
In its efforts to innovate, Volition has celebrated a series of significant milestones with the Nu.Q® Discover program:
- The first successful commercial sale of their High Throughput Synthetic Sepsis method, which enables real-time measurement of Neutrophil Extracellular Traps' activation.
- The initiation of a historic agreement with a leading pharmaceutical company to leverage Volition's biomarkers in a longitudinal Phase 1/2b study, marking it as a pioneering in-human clinical trial.
- Establishing a co-marketing agreement with Hologic Diagenode to further extend their reach and impact.
About Medical & Biological Laboratories Co., Ltd
Founded in 1969, MBL stands as a cornerstone in the realm of antibody production in Japan. Their extensive work encompasses research, development, and manufacturing of in vitro diagnostic reagents, and they have also ventured into genetic diagnostics. MBL offers a broad spectrum of reagents targeting autoimmune diseases and oncology, striving to enhance personalized medicine.
Volition's Broader Vision
VolitionRx Limited is devoted to pushing the boundaries of epigenetics to give hope in diagnosing and monitoring life-altering conditions. Their mission focuses on creating accessible blood tests that allow for earlier detection and better patient management, which can improve patient outcomes considerably.
The company’s operational headquarters lie in Belgium, complemented by an innovation laboratory in the United States and an administrative office in London. With a commitment to enhancing patient care, VolitionRx continues striving to innovate and provide tools for improving health outcomes globally.
Frequently Asked Questions
1. What is the role of Medical & Biological Laboratories in VolitionRx's strategy?
Medical & Biological Laboratories will act as a distributor for VolitionRx's Nu.Q® Discover assays in Japan, enhancing access to innovative diagnostics in the region.
2. How does Nu.Q® Discover contribute to clinical research?
Nu.Q® Discover offers advanced assays for rapid epigenetic profiling, essential for drug development and research, especially in understanding disease mechanisms.
3. What is VolitionRx's future growth outlook?
VolitionRx anticipates continued substantial revenue growth, particularly due to the expanding market and the success of its Nu.Q® Discover program.
4. What innovations have been made under the Nu.Q® Discover program?
Nu.Q® Discover has seen significant milestones, including the first commercial sale of its sepsis detection method and key partnerships for clinical studies.
5. How does VolitionRx aim to support early disease detection?
By providing accessible and cost-effective blood tests, VolitionRx focuses on early detection and monitoring of various diseases, improving patient outcomes.
